AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37103592 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 37103592 — intervention group
Group type: EXPERIMENTAL
Intervention: PED-t and CBT (combined analysis)
Number of subjects: 0
Study 37103597 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes4Me mobile app
Number of subjects: 107
Study 37103656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild malnutrition
Number of subjects: 12652
Study 37103656 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate malnutrition
Number of subjects: 12652
Study 37103656 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malnutrition
Number of subjects: 12652
Study 37103656 — intervention group
Group type: COMPARATOR
Intervention: Absent malnutrition
Number of subjects: 12652
Study 37103658 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 23
Study 37103658 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 23
Study 37103658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 37103682 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) 5 times a week for 5 weeks, consisting of high-intensity training with sets increasing from 5 to 9 over the training period.
Number of subjects: 40
Study 37103682 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) 5 times a week for 5 weeks.
Number of subjects: 40
Study 37103682 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation program activities including aerobic exercise, resistance training, and educational class.
Number of subjects: 40
Study 37103756 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal multimodal MRI
Number of subjects: 41
Study 37103756 — intervention group
Group type: COMPARATOR
Intervention: Clinical prognostic factors
Number of subjects: 41
Study 37103915 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone, dosage and duration not available
Number of subjects: 0
Study 37103915 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 37103935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 37103991 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month behavioral weight loss intervention delivered via Facebook
Number of subjects: 62
Study 37103991 — intervention group
Group type: COMPARATOR
Intervention: 6-month behavioral weight loss intervention delivered via in-person groups
Number of subjects: 62
Study 37103991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained participation defined by intervention meeting attendance or visible engagement in the Facebook group
Number of subjects: 62
Study 37103991 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent weight loss at 6 and 12 months
Number of subjects: 62
Study 37104214 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-Pump Inhibitors (PPIs)
Number of subjects: 0
Study 37104214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37104280 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Web intervention (internet-based parent training)
Number of subjects: 0
Study 37104280 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (matched sample of adolescents with no prior experience of PATHS)
Number of subjects: 0
Study 37104305 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated baby wrap
Number of subjects: 0
Study 37104305 — intervention group
Group type: COMPARATOR
Intervention: Sham-treated wrap (placebo)
Number of subjects: 0
Study 37104481 — intervention group
Group type: EXPERIMENTAL
Intervention: FITC-sinistrin clearance during CRRT
Number of subjects: 5
Study 37104481 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal measurement of FITC-sinistrin
Number of subjects: 5
Study 37104481 — intervention group
Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 5
Study 37104641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 113
Study 37104746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 0
Study 37104746 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study 37104748 — intervention group
Group type: COMPARATOR
Intervention: Dose-escalated radiotherapy (RT) alone
Number of subjects: 1492
Study 37104748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy (RT) with short-term androgen deprivation (STAD)
Number of subjects: 1492
Study 37104758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of margetuximab and pembrolizumab
Number of subjects: 86
Study 37104758 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 86
Study 37104758 — intervention group
Group type: EXPERIMENTAL
Intervention: Current ERBB2 status
Number of subjects: 86
Study 37104870 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (arm A)
Number of subjects: 87
Study 37104870 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cixutumumab (arm B)
Number of subjects: 87
Study 37104871 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE intervention
Number of subjects: 71
Study 37104871 — intervention group
Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 71
Study 37104931 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 0
Study 37104944 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile (Q4) of FT3/FT4 ratio
Number of subjects: 3648
Study 37104979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 2423
Study 37104979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study 37104979 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD-LFS
Number of subjects: 2423
Study 37104979 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 2423
Study 37105060 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparo-endoscopic single-site surgery (LESS)
Number of subjects: 107
Study 37105060 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 107
Study 37105162 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalographic neurofeedback training
Number of subjects: 0
Study 37105210 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic haematopoietic stem cell transplantation (HSCT)
Number of subjects: 99
Study 37105210 — intervention group
Group type: COMPARATOR
Intervention: Non-allogeneic HSCT therapy
Number of subjects: 99
Study 37105210 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 99
Study 37105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH measurement using an AMH automated assay
Number of subjects: 4556
Study 37105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut-off for PCOS diagnosis
Number of subjects: 4556
Study 37105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, ethnicity, obesity, PCOS, and endometrioma cystectomy history
Number of subjects: 4556
Study 37105265 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 476
Study 37105265 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 476
Study 37105304 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT plus EGFR-TKI
Number of subjects: 62
Study 37105304 — intervention group
Group type: COMPARATOR
Intervention: EGFR-TKI alone
Number of subjects: 62
Study 37105318 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change technique (BCT) intervention
Number of subjects: 42
Study 37105430 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered exercise-based cardiac rehabilitation (EBCR)
Number of subjects: 1500
Study 37105430 — intervention group
Group type: COMPARATOR
Intervention: Center-based exercise-based cardiac rehabilitation (EBCR)
Number of subjects: 1500
Study 37105430 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote EBCR
Number of subjects: 1500
Study 37105430 — intervention group
Group type: COMPARATOR
Intervention: Control (center-based EBCR)
Number of subjects: 1500
Study 37105430 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of major adverse cardiovascular events
Number of subjects: 1500
Study 37105430 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety monitoring of serious adverse events
Number of subjects: 1500
Study 37105430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 1500
Study 37105508 — intervention group
Group type: COMPARATOR
Intervention: ACT
Number of subjects: 234
Study 37105508 — intervention group
Group type: COMPARATOR
Intervention: BATD
Number of subjects: 234
Study 37105508 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU
Number of subjects: 234
Study 37105511 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive repair
Number of subjects: 5510
Study 37105511 — intervention group
Group type: COMPARATOR
Intervention: Proximal repair
Number of subjects: 5510
Study 37105689 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (specific types not detailed)
Number of subjects: 1800
Study 37105689 — intervention group
Group type: EXPERIMENTAL
Intervention: Data extraction from electronic patient files and historical databases
Number of subjects: 1800
Study 37105693 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with very high neutralising antibody titre administered within 7 days of symptom onset plus standard of care
Number of subjects: 1020
Study 37105693 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 1020
Study 37105694 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG), brainstem evoked potentials, transcranial doppler, bedside haemodynamic monitors
Number of subjects: 90
Study 37105705 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR with carbon dioxide flushing (TEVAR-CO)
Number of subjects: 120
Study 37105705 — intervention group
Group type: COMPARATOR
Intervention: TEVAR with saline flushing (control)
Number of subjects: 120
Study 37105885 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 2
Study 37105892 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 1184
Study 37105892 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1184
Study 37105892 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib and RV1
Number of subjects: 1184
Study 37106078 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based childcare full-time (40 h/week)
Number of subjects: 3503
Study 37106078 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based childcare full-time (40 h/week) for families with income < $50,000 CDN
Number of subjects: 3503
Study 37106099 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral plasma concentrations of succinate obtained during coronary revascularization
Number of subjects: 111
Study 37106099 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral plasma concentrations of other metabolites
Number of subjects: 111
Study 37106164 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects without MetS
Number of subjects: 563
Study 37106164 — intervention group
Group type: COMPARATOR
Intervention: Subjects with MetS
Number of subjects: 563
Study 37106206 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE)
Number of subjects: 222
Study 37106206 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 222
Study 37106206 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration (LCBDE) failure
Number of subjects: 222
Study 37106206 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of initial stay
Number of subjects: 222
Study 37106206 — intervention group
Group type: EXPERIMENTAL
Intervention: Total length of hospitalization
Number of subjects: 222
Study 37106206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of emergency readmissions
Number of subjects: 222
Study 37106220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation of the efferent limb with 500 ml of saline chloride solution mixed with a thickening agent (Resource) for 2 weeks before ileostomy reversal.
Number of subjects: 0
Study 37106220 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 37106319 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TAPA block (bupivacaine 0.25%, 25 ml)
Number of subjects: 76
Study 37106319 — intervention group
Group type: COMPARATOR
Intervention: OSTAP block (bupivacaine 0.25%, 25 ml)
Number of subjects: 76
Study 37106319 — intervention group
Group type: EXPERIMENTAL
Intervention: M-TAPA block
Number of subjects: 76
Study 37106319 — intervention group
Group type: COMPARATOR
Intervention: OSTAP block
Number of subjects: 76
Study 37106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intubation within the first 24 hours of ICU admission
Number of subjects: 4198
Study 37106321 — intervention group
Group type: COMPARATOR
Intervention: Late intubation (not explicitly defined in the abstract)
Number of subjects: 4198
Study 37106343 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (hyperbaric bupivacaine 0.5%)
Number of subjects: 421
Study 37106343 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (intravenous propofol/ketamine/sodium thiopental)
Number of subjects: 421
Study 37106344 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anterior nasal swab (ANS)
Number of subjects: 249
Study 37106344 — intervention group
Group type: COMPARATOR
Intervention: Combined throat and anterior nasal swab (CTN)
Number of subjects: 249
Study 37106374 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated sdLDL-C
Number of subjects: 200
Study 37106374 — intervention group
Group type: COMPARATOR
Intervention: Total LDL-C (calculated by Friedewald equation)
Number of subjects: 200
Study 37106374 — intervention group
Group type: EXPERIMENTAL
Intervention: Small LDL particles (S-LDLP) and small HDL particles (S-HDLP), along with large and medium TG-rich lipoproteins (TRLPs)
Number of subjects: 200
Study 37106411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 410
Study 37106411 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 410
Study 37106460 — intervention group
Group type: EXPERIMENTAL
Intervention: Paretic upper limb of stroke patients
Number of subjects: 30
Study 37106460 — intervention group
Group type: EXPERIMENTAL
Intervention: FuncUseRatio30
Number of subjects: 30
Study 37106460 — intervention group
Group type: EXPERIMENTAL
Intervention: UseHoursRatio, FuncUseRatio30, JR50
Number of subjects: 30
Study 37106559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic group cognitive behaviour therapy (CBT)
Number of subjects: 156
Study 37106559 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis-specific group cognitive behaviour therapy (CBT)
Number of subjects: 156
Study 37107208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to a Mediterranean diet (AMD)
Number of subjects: 67
Study 37107735 — intervention group
Group type: EXPERIMENTAL
Intervention: KiSS intervention arm receiving urge management skills training
Number of subjects: 0
Study 37107735 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 4 of Sedentary Time (ST) and ≥300 min/week of Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 1 of ST and 150-299 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 1 of ST and 76-149 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 3 of ST and 76-149 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartiles 1, 2, and 3 of ST with 0-74 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 3 of ST and 150-299 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartiles 1 and 3 of ST and 76-149 min/week of MVPA
Number of subjects: 0
Study 37107844 — intervention group
Group type: COMPARATOR
Intervention: Quartile 1 of ST and 0-74 min/week of MVPA
Number of subjects: 0
Study 37107849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=564)
Number of subjects: 940
Study 37107849 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=376)
Number of subjects: 940
Study 37107903 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions (automatic oscillometric device and personalized text messages)
Number of subjects: 231
Study 37107903 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical treatment (UCT) without technology
Number of subjects: 231
Study 37107943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exergame program (balance and lower-extremity muscle strength) for 8 weeks, 50 min three times a week
Number of subjects: 57
Study 37107943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 57
Study 37107943 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exergame program
Number of subjects: 57
Study 37108484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD), specific details on dosage and duration not available.
Number of subjects: 0
Study 37108484 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA)
Number of subjects: 0
Study 37109179 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory steady-state responses (ASSR) and auditory brainstem response (ABR) used to evaluate hearing.
Number of subjects: 50
Study 37109303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium-chloride capsules
Number of subjects: 271
Study 37109303 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 271
Study 37109468 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolysis (PE; n = 26)
Number of subjects: 52
Study 37109468 — intervention group
Group type: COMPARATOR
Intervention: Deep Dry Needling (DDN; n = 26)
Number of subjects: 52
Study 37111136 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (LD) supplement containing 440 mg of Fucoxanthin and Guarana
Number of subjects: 61
Study 37111136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 61
Study 37111382 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) treatment
Number of subjects: 276
Study 37113325 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote home-based upper extremity self-training program
Number of subjects: 15
Study 37113325 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and ecological momentary assessments
Number of subjects: 15
Study 37113515 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training (HIT) program for 12 weeks, monitored exercise sessions on treadmill, 4 min × 4 manner, three times a week.
Number of subjects: 16
Study 37113515 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 patients)
Number of subjects: 16
Study 37113674 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS 3G (third-generation drug-eluting resorbable magnesium scaffold)
Number of subjects: 116
Study 37113733 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 150
Study 37113754 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 37113754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37114054 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus platinum-irinotecan (IP/IC)
Number of subjects: 53
Study 37114054 — intervention group
Group type: COMPARATOR
Intervention: EP/EC plus PD-L1 inhibitor (historical control)
Number of subjects: 53
Study 37114054 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related adverse events in IP/IC plus camrelizumab group
Number of subjects: 53
Study 37114393 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel prognostic index combining baseline metabolic tumour volume (MTV) with clinical and pathological parameters.
Number of subjects: 289
Study 37114393 — intervention group
Group type: COMPARATOR
Intervention: Ann Arbor staging and NCCN-IPI (as control for comparison).
Number of subjects: 289
Study 37114918 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Fat Transfer (AFT)
Number of subjects: 46
Study 37114918 — intervention group
Group type: COMPARATOR
Intervention: Implant-Based Reconstruction (IBR)
Number of subjects: 46
Study 37114990 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ-12 (Kansas City Cardiomyopathy Questionnaire-12)
Number of subjects: 21
Study 37114990 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ-12
Number of subjects: 21
Study 37115054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin sustained-release (SR) tablet (150 mg once a day)
Number of subjects: 130
Study 37115054 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin immediate-release (IR) capsule (75 mg twice a day)
Number of subjects: 130
Study 37115132 — intervention group
Group type: EXPERIMENTAL
Intervention: No-implant interatrial shunt
Number of subjects: 28
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs/ARNIs
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: MRAs
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal doses of beta-blockers
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal doses of ACEIs/ARBs/ARNIs
Number of subjects: 464
Study 37115135 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 GDMT classes
Number of subjects: 464